Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kathryn R. Meshaw"'
Autor:
Jeffrey J Roix, S D Harrison, Elizabeth A Rainbolt, Kathryn R Meshaw, Avery S McMurry, Peter Cheung, Saurabh Saha
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e101708 (2014)
Approved drugs target approximately 400 different mechanisms of action, of which as few as 60 are currently used as anti-cancer therapies. Given that on average it takes 10-15 years for a new cancer therapeutic to be approved, and the recent success
Externí odkaz:
https://doaj.org/article/6f89503248c8437e93e3a5ac924a0f08
Autor:
Diane M. Boucher, David Sorrell, Kathryn R. Meshaw, Dean Welsch, Michael J. Wick, William Markland, Alex Aronov, Saurabh Saha, Matthew J. Fitzgibbon, Mark N. Namchuk, Ramin Samadani, Gabriel Martinez-Botella, Michael R. Hale, Ursula A. Germann, Caroline Emery, Brinley Furey, Russell R. Hoover, Decrescenzo Gary A, Paul Shapiro, Anna L. Groover, Jeffrey James Roix
Publikováno v:
Molecular Cancer Therapeutics. 16:2351-2363
Aberrant activation of signaling through the RAS–RAF–MEK–ERK (MAPK) pathway is implicated in numerous cancers, making it an attractive therapeutic target. Although BRAF and MEK-targeted combination therapy has demonstrated significant benefit b
Autor:
Saurabh Saha, Kathryn R. Meshaw, Peter C. F. Cheung, Avery S. McMurry, Jeffrey James Roix, S. D. Harrison, Elizabeth Rainbolt
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e101708 (2014)
PLoS ONE
PLoS ONE
Approved drugs target approximately 400 different mechanisms of action, of which as few as 60 are currently used as anti-cancer therapies. Given that on average it takes 10–15 years for a new cancer therapeutic to be approved, and the recent succes
Autor:
Roix, Jeffrey J.1 jroix@biomed-valley.com, Harrison, S. D.2, Rainbolt, Elizabeth A.2, Meshaw, Kathryn R.2, McMurry, Avery S.2, Cheung, Peter1, Saha, Saurabh1
Publikováno v:
PLoS ONE. Aug2014, Vol. 9 Issue 8, p1-8. 8p.